about
Transient myeloproliferative disorder in a newborn with down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: A case report.Childhood central nervous system tumour mortality and survival in Southern and Eastern Europe (1983-2014): Gaps persist across 14 cancer registries.Childhood central nervous system tumours: Incidence and time trends in 13 Southern and Eastern European cancer registries.History of Maternal Fetal Loss and Childhood Leukaemia Risk in Subsequent Offspring: Differentials by Miscarriage or Stillbirth History and Disease Subtype.Socioeconomic disparities in survival from childhood leukemia in the United States and globally: a meta-analysis.Mannose binding lectin and ficolin-2 polymorphisms are associated with increased risk for bacterial infections in children with B acute lymphoblastic leukemia.Association of fetal loss with recent parvovirus infection and other demographic prognostic risk factors.Bilateral Eyelid Ptosis, Attributed to Vincristine, Treated Successfully with Pyridoxine and Thiamine in a Child with Acute Lymphoblastic Leukemia.Tibial pseudotumor in a child with hemophilia.Improving the outcome of pregnancy in essential thrombocythaemia: The role of aspirin.Maternal and childhood consumption of coffee, tea and cola beverages in association with childhood leukemia: a meta-analysis.Endothelial activation and inflammation biomarkers in children and adolescents with sickle cell disease.Congenital acute lymphoblastic leukemia case with a novel t(2:4:11) (p21:q21:q23) translocation.Pregnancy and oral health: utilisation of dental services during pregnancy in northern GreeceThrombomodulin and von Willebrand factor: relation to endothelial dysfunction and disease outcome in children with acute lymphoblastic leukemiaCytogenetic abnormalities and monosomal karyotypes in children and adolescents with acute myeloid leukemia: correlations with clinical characteristics and outcomeCombined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients
P50
Q38565002-ADD5EF38-0882-4D59-9C39-1FB5272B663CQ40311027-0C8F089C-1852-49A0-B2D3-A9214FBD7082Q40942760-962BD0BC-57FF-43E6-86A1-75DF27318DF7Q41586643-4D8E29B0-6092-4490-AEC9-32B387FF0A8BQ41665595-01904A75-6E7F-46DE-AA6A-72C189988D74Q42231801-F38EA9C8-918D-4D07-BD5F-D12BEB68B08DQ42236033-D0263940-1409-4C9F-B5F3-50372B5BFE2EQ42720703-193CAA89-587B-4F1A-B054-586FBD9E695EQ45873816-240DEA4A-8F29-4A15-88E5-8BEED5FE6BBCQ46661246-3ED2B6AC-DB6E-4112-B15E-BCED206A62CFQ50860433-B2315F09-3CD3-4119-9EAD-9F18A9AC6A85Q50872342-6DFBF5D1-D832-4CE3-B7E0-BC8E0460FBB0Q54538463-E1D6D9DA-7F7B-4352-885B-22EF98E137A7Q80676598-68DC05E3-66B4-4338-953A-BFAA8DD3BBEFQ82847708-2B134320-69B1-4C21-B58D-643E38C0F6E5Q86121149-73FDF758-BA66-44E1-9FFB-B00ADF6F8853Q86973574-715E46BE-6953-48F9-ADA2-B6DDE6AC0145
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Emmanouil S Hatzipantelis
@en
Emmanouil S Hatzipantelis
@nl
type
label
Emmanouil S Hatzipantelis
@en
Emmanouil S Hatzipantelis
@nl
prefLabel
Emmanouil S Hatzipantelis
@en
Emmanouil S Hatzipantelis
@nl
P31
P496
0000-0002-7535-2970